BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32561369)

  • 1. Comparative analysis of prescribing patterns of tetracycline class antibiotics and spironolactone between advanced practice providers and physicians in the treatment of acne vulgaris.
    Guzman AK; Barbieri JS
    J Am Acad Dermatol; 2021 Apr; 84(4):1119-1121. PubMed ID: 32561369
    [No Abstract]   [Full Text] [Related]  

  • 2. The efficacy and safety of amoxicillin, trimethoprim-sulfamethoxazole, and spironolactone for treatment-resistant acne vulgaris.
    Turowski CB; James WD
    Adv Dermatol; 2007; 23():155-63. PubMed ID: 18159900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spironolactone for the Treatment of Acne: A 4-Year Retrospective Study.
    Grandhi R; Alikhan A
    Dermatology; 2017; 233(2-3):141-144. PubMed ID: 28472793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of topical spironolactone in treatment of acne.
    Bagherani N
    Dermatol Ther; 2015; 28(3):176. PubMed ID: 25471010
    [No Abstract]   [Full Text] [Related]  

  • 5. The diagnosis and management of acne.
    Sidbury R; Paller AS
    Pediatr Ann; 2000 Jan; 29(1):17-24. PubMed ID: 10941764
    [No Abstract]   [Full Text] [Related]  

  • 6. Spironolactone for 
Adult Female Acne.
    Friedman AJ
    Cutis; 2015 Oct; 96(4):216-7. PubMed ID: 27141564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Overview of Acne Therapy, Part 2: Hormonal Therapy and Isotretinoin.
    Marson JW; Baldwin HE
    Dermatol Clin; 2019 Apr; 37(2):195-203. PubMed ID: 30850042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the efficacy of 5% topical spironolactone gel and placebo in the treatment of mild and moderate acne vulgaris: a randomized controlled trial.
    Afzali BM; Yaghoobi E; Yaghoobi R; Bagherani N; Dabbagh MA
    J Dermatolog Treat; 2012 Feb; 23(1):21-5. PubMed ID: 20964565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in prescribing behavior of systemic agents used in the treatment of acne among dermatologists and nondermatologists: A retrospective analysis, 2004-2013.
    Barbieri JS; James WD; Margolis DJ
    J Am Acad Dermatol; 2017 Sep; 77(3):456-463.e4. PubMed ID: 28676330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A matched cohort study evaluating whether spironolactone or tetracycline-class antibiotic use among female acne patients is associated with breast cancer development risk.
    Garate D; Thang CJ; Golovko G; Wilkerson MG; Barbieri JS
    Arch Dermatol Res; 2024 May; 316(5):196. PubMed ID: 38775970
    [No Abstract]   [Full Text] [Related]  

  • 11. Spironolactone in dermatology: uses in acne and beyond.
    Searle TN; Al-Niaimi F; Ali FR
    Clin Exp Dermatol; 2020 Dec; 45(8):986-993. PubMed ID: 32844462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne.
    Farquhar C; Lee O; Toomath R; Jepson R
    Cochrane Database Syst Rev; 2001; (4):CD000194. PubMed ID: 11687072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne.
    Lee O; Farquhar C; Toomath R; Jepson R
    Cochrane Database Syst Rev; 2000; (2):CD000194. PubMed ID: 10796700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne.
    Farquhar C; Lee O; Toomath R; Jepson R
    Cochrane Database Syst Rev; 2003; (4):CD000194. PubMed ID: 14583916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FASCE, the benefit of spironolactone for treating acne in women: study protocol for a randomized double-blind trial.
    Poinas A; Lemoigne M; Le Naour S; Nguyen JM; Schirr-Bonnans S; Riche VP; Vrignaud F; Machet L; Claudel JP; Leccia MT; Hainaut E; Beneton N; Dert C; Boisrobert A; Flet L; Chiffoleau A; Corvec S; Khammari A; Dréno B
    Trials; 2020 Jun; 21(1):571. PubMed ID: 32586344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of Treatment Switching for Spironolactone Compared to Oral Tetracycline-Class Antibiotics for Women With Acne: A Retrospective Cohort Study 2010-2016.
    Barbieri JS; Choi JK; Mitra N; Margolis DJ
    J Drugs Dermatol; 2018 Jun; 17(6):632-638. PubMed ID: 29879250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic Review.
    Layton AM; Eady EA; Whitehouse H; Del Rosso JQ; Fedorowicz Z; van Zuuren EJ
    Am J Clin Dermatol; 2017 Apr; 18(2):169-191. PubMed ID: 28155090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical antibiotic monotherapy prescribing practices in acne vulgaris.
    Hoover WD; Davis SA; Fleischer AB; Feldman SR
    J Dermatolog Treat; 2014 Apr; 25(2):97-9. PubMed ID: 24171409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of spironolactone for the treatment of acne in adolescent girls.
    Canu D; Mary-Prey S; Legrand A; Leauté-Labreze C
    Ann Dermatol Venereol; 2024 Jun; 151(2):103281. PubMed ID: 38781891
    [No Abstract]   [Full Text] [Related]  

  • 20. Duration of oral tetracycline-class antibiotic therapy and use of topical retinoids for the treatment of acne among general practitioners (GP): A retrospective cohort study.
    Barbieri JS; Hoffstad O; Margolis DJ
    J Am Acad Dermatol; 2016 Dec; 75(6):1142-1150.e1. PubMed ID: 27502311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.